The active pharmaceutical ingredient (API) market for cefdinir is a segment of the broader antibiotic market. Cefdinir is a third-generation cephalosporin antibiotic used to treat various bacterial infections [1].
What bacterial infections does cefdinir treat?
Cefdinir is prescribed for infections such as acute otitis media (ear infections), pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections [1].
How does cefdinir work?
As a cephalosporin, cefdinir works by inhibiting bacterial cell wall synthesis, which leads to bacterial death [1].
When did cefdinir become available and what is its patent status?
Cefdinir was approved by the U.S. Food and Drug Administration (FDA) in 1997 [2]. Patent protection for cefdinir has expired, allowing for the development and sale of generic versions [3]. Information on specific patent expiry dates and related litigation can be found on resources like DrugPatentWatch.com [4].
Who manufactures cefdinir API and finished drug products?
The manufacturing of cefdinir API involves various chemical synthesis companies globally. Finished drug products containing cefdinir are produced by multiple pharmaceutical companies. Generic versions are widely available from numerous manufacturers [3].
What are the key drivers in the cefdinir API market?
The market for cefdinir API is influenced by the demand for antibiotics, the prevalence of bacterial infections treatable by cefdinir, and the availability and pricing of generic alternatives [3]. Regulatory approvals and quality standards for API manufacturing also play a significant role.
What are the alternatives to cefdinir?
Other antibiotics are available to treat bacterial infections, including other cephalosporins, penicillins, macrolides, and fluoroquinolones, depending on the type and severity of the infection and local resistance patterns [1].
What is the market size and growth outlook for cefdinir API?
Specific market size figures for cefdinir API alone are not readily available, but the overall cephalosporin market is substantial. The growth outlook is generally tied to the broader antibiotic market, which faces challenges from antibiotic resistance and competition from newer drug classes [3].
What regulatory considerations affect cefdinir API production?
Cefdinir API manufacturers must adhere to stringent quality control standards and Good Manufacturing Practices (GMP) mandated by regulatory bodies like the FDA. DrugMaster Files (DMFs) are often submitted to regulatory agencies to support applications for finished drug products [1, 4].
What are the risks associated with cefdinir use?
Common side effects of cefdinir include diarrhea, nausea, and rash. More serious risks, though rare, can include severe allergic reactions and Clostridioides difficile-associated diarrhea [1].
Sources:
[1] Cefdinir - National Library of Medicine
[2] FDA Approved Drug Products - Cefdinir
[3] Cefdinir - Wikipedia
[4] DrugPatentWatch.com